Drug Interactions between apixaban and Metoprolol Succinate ER
This report displays the potential drug interactions for the following 2 drugs:
- apixaban
- Metoprolol Succinate ER (metoprolol)
Interactions between your drugs
No interactions were found between apixaban and Metoprolol Succinate ER. This does not necessarily mean no interactions exist. Always consult your healthcare provider.
apixaban
A total of 322 drugs are known to interact with apixaban.
- Apixaban is in the drug class factor Xa inhibitors.
-
Apixaban is used to treat the following conditions:
- Deep Vein Thrombosis
- Deep Vein Thrombosis Prophylaxis after Hip Replacement Surgery
- Deep Vein Thrombosis Prophylaxis after Knee Replacement Surgery
- Deep Vein Thrombosis, Prophylaxis
- Prevention of Thromboembolism in Atrial Fibrillation
- Pulmonary Embolism
- Thromboembolic Stroke Prophylaxis
- Venous Thromboembolism
Metoprolol Succinate ER
A total of 478 drugs are known to interact with Metoprolol Succinate ER.
- Metoprolol succinate er is in the drug class cardioselective beta blockers.
- Metoprolol succinate er is used to treat the following conditions:
Drug and food interactions
metoprolol food
Applies to: Metoprolol Succinate ER (metoprolol)
Food can enhance the levels of metoprolol in your body. You should take metoprolol at the same time each day, preferably with or immediately following meals. This will make it easier for your body to absorb the medication. Avoid drinking alcohol, which could increase drowsiness and dizziness while you are taking metoprolol. Metoprolol is only part of a complete program of treatment that also includes diet, exercise, and weight control. Follow your diet, medication, and exercise routines very closely.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See Also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.